Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Neuron replacement therapy

Cell_Gene_Therapy

Cell and Gene Therapy Today—March 26, 2026

This week’s Gene and Cell Therapy update highlights regulatory approvals,…

Cell_Gene_Therapy

Cell and Gene Therapy Today—December 18, 2025

This week’s Cell & Gene Therapy update highlights major developments,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

Tags

Behcet’s disease Bivamelagon Cardiac Rehab Cardiovascular Risk chronic disease prevention Competitive Intelligence Process Duchenne MD Duvelisib Elanco Elecoglipron EN001 Enspryng epigenetic editing ESC2025 Exosome Vaccines FDA Breakthrough Therapy Designation Gaucher Disease Type 3 GLP1 drugs healthcare tech IgG4 Related Disease IL-1β KRAS Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics Molluscum Contagiosum Nutrition Science ORIC Pharmaceuticals Parkinson’s Disease Apathy pediatric rare disease PONLIMSI Relacorilant robotic surgery RRMS Saphnelo Sjögrens Disease Sobi Spontaneous coronary artery dissection STAR-LLD Taysha Time-Restricted Feeding Tricuspid regurgitation type one diabetes

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

TAGS

Behcet’s disease Bivamelagon Cardiac Rehab Cardiovascular Risk chronic disease prevention Competitive Intelligence Process Duchenne MD Duvelisib Elanco Elecoglipron EN001 Enspryng epigenetic editing ESC2025 Exosome Vaccines FDA Breakthrough Therapy Designation Gaucher Disease Type 3 GLP1 drugs healthcare tech IgG4 Related Disease IL-1β KRAS Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics Molluscum Contagiosum Nutrition Science ORIC Pharmaceuticals Parkinson’s Disease Apathy pediatric rare disease PONLIMSI Relacorilant robotic surgery RRMS Saphnelo Sjögrens Disease Sobi Spontaneous coronary artery dissection STAR-LLD Taysha Time-Restricted Feeding Tricuspid regurgitation type one diabetes

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy